Source comparison
Best SS-31 Dosage Aging 2026: Comparison by Research Application
Baseline mitochondrial aging studies (healthy models) 5–10mg weekly Once per week 8–12 weeks Standard protocol for examining age-related decline in ATP production and ROS management. Sufficient to saturate cardiolipin binding without excess Acute mitochondrial
This comparison does not assign a generated winner or score.
- Baseline mitochondrial aging studies (healthy models)
- 5–10mg weekly
- Once per week
- 8–12 weeks
- Standard protocol for examining age-related decline in ATP production and ROS management. Sufficient to saturate cardiolipin binding without excess
- Acute mitochondrial rescue (disease models)
- 10–20mg
- Twice weekly
- 4–8 weeks
- Higher dose justified when mitochondrial damage is severe; split dosing maintains plasma presence during critical intervention window
- Cardiolipin oxidation prevention (preventive protocols)
- 5–8mg weekly
- 12–24 weeks
- Lower end of range effective for subjects without existing dysfunction; focus is stabilisation rather than rescue
- Pharmacokinetic / bioavailability studies
- 2.5–15mg
- Variable (acute to weekly)
- Single dose to 4 weeks
- Dose adjusted based on specific PK endpoints; often uses tracer methods alongside therapeutic dosing
- Long-term healthspan extension models
- 8–12mg weekly
- 24+ weeks
- Mid-range dose balances efficacy with cost; longest-running primate studies use this tier